Melanoma (stage III or IV) - ipilimumab: review decision - April 2015 information
History
A list of downloadable documents created during development.
Background information
-
-
Melanoma (stage III or IV) - ipilimumab: appendix A - GE decision paper - April 2015
-
Melanoma (stage III or IV) - ipilimumab: appendix A - GE decision paper - April 2015 (PDF 77 KB)
-
Melanoma (stage III or IV) - ipilimumab: review proposal - January 2015 information
-
Melanoma (stage III or IV) - ipilimumab: appendix B - GE proposal paper - December 2014
-
Melanoma (stage III or IV) - ipilimumab: appendix B - GE proposal paper - December 2014 (PDF 209 KB)
-
Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders
-
Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders (PDF 99 KB)
Melanoma (stage III or IV) - ipilimumab: equality impact assessment - guidance development
-
Melanoma (stage III or IV) - ipilimumab: equality impact assessment - guidance development
-
Melanoma (stage III or IV) - ipilimumab: final appraisal determination
-
Melanoma (stage III or IV) - ipilimumab: final appraisal determination information
-
Melanoma (stage III or IV) - ipilimumab: final appraisal determination guidance
-
Melanoma (stage III or IV) - ipilimumab: final appraisal determination guidance (PDF 285 KB)
-
Melanoma (stage III or IV) - ipilimumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Melanoma (stage III or IV) - ipilimumab: updated analysis with revised patient access scheme from Bristol Myers-Squibb
-
-
Melanoma (stage III or IV) - ipilimumab: revised addendum by Liverpool reviews and implementation group (LRiG)
-
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PAS Submission)
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PAS Submission) (PDF 488 KB)
-
Melanoma (stage III or IV) - ipilimumab: addendum by Liverpool reviews and implementation group (LRiG)
-
-
Melanoma (stage III or IV) - ipilimumab: consultee and commentator comments on the ACD
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PDF 1.05 MB)
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb - supplementary letter
-
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb - supplementary letter (PDF 18 KB)
-
Melanoma (stage III or IV) - ipilimumab: British Association Skin Cancer Specialist Nurses
-
-
Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists
-
Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists (PDF 67 KB)
-
Melanoma (stage III or IV) - ipilimumab: Department of Health
-
Melanoma (stage III or IV) - ipilimumab: Department of Health (PDF 66 KB)
-
Melanoma (stage III or IV) - ipilimumab: Factor 50
-
Melanoma (stage III or IV) - ipilimumab: Factor 50 (PDF 88 KB)
-
Melanoma (stage III or IV) - ipilimumab: Myfanwy Townsend Melanoma Research Fund
-
Melanoma (stage III or IV) - ipilimumab: Myfanwy Townsend Melanoma Research Fund (PDF 13 KB)
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing (PDF 60 KB)
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Pathologists
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Pathologists (PDF 6.4 KB)
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO
-
-
Melanoma (stage III or IV) - ipilimumab: Skcin: The Karen Clifford Skin Cancer Charity
-
Melanoma (stage III or IV) - ipilimumab: Skcin: The Karen Clifford Skin Cancer Charity (PDF 214 KB)
-
Melanoma (stage III or IV) - ipilimumab: Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research
-
-
Melanoma (stage III or IV) - ipilimumab: Liverpool reviews and implementation group
-
Melanoma (stage III or IV) - ipilimumab: Liverpool reviews and implementation group (PDF 136 KB)
-
Melanoma (stage III or IV) - ipilimumab: Dr Paul Lorigan
-
Melanoma (stage III or IV) - ipilimumab: Dr Paul Lorigan (PDF 57 KB)
-
Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website
-
Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website
-
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 1
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 1 (PDF 1.89 MB)
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 2
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 2 (PDF 2.63 MB)
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 3
-
Melanoma (stage III or IV) - ipilimumab: MP letters batch 3 (PDF 2.56 MB)
-
Melanoma (stage III or IV) - ipilimumab: parliamentry report
-
Melanoma (stage III or IV) - ipilimumab: parliamentry report (PDF 1.55 MB)
Melanoma (stage III or IV) - ipilimumab: appraisal consultation
-
Melanoma (stage III or IV) - ipilimumab: appraisal consultation
-
Melanoma (stage III or IV) - ipilimumab: appraisal consultation document information
-
Melanoma (stage III or IV) - ipilimumab: evaluation report
-
Melanoma (stage III or IV) - ipilimumab: pre-meeting briefing
-
Melanoma (stage III or IV) - ipilimumab: pre-meeting briefing (PDF 378 KB)
-
Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report
-
Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report
-
Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report (PDF 1.28 MB)
-
Melanoma (stage III or IV) - ipilimumab: ERG report - revised table 1
-
Melanoma (stage III or IV) - ipilimumab: ERG report - revised table 1 (PDF 37 KB)
-
Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report - factual accuracy check
-
-
Melanoma (stage III or IV) - ipilimumab: manufacturers submission Bristol Myers-Squibb
-
Melanoma (stage III or IV) - ipilimumab: manufacturers submission Bristol Myers-Squibb (PDF 3.72 MB)
-
Melanoma (stage III or IV) - ipilimumab: clarification
-
Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 1
-
Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 1 (PDF 79 KB)
-
Melanoma (stage III or IV) - ipilimumab: manufacturer response to the NICE clarification letter 1
-
-
Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 2
-
Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 2 (PDF 77 KB)
-
Melanoma (stage III or IV) - ipilimumab: manufacturer response to the NICE clarification letter 2
-
-
Melanoma (stage III or IV) - ipilimumab: patient group, professional group and NHS organisation submission statements
-
Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists
-
Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists (PDF 85 KB)
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing (PDF 88 KB)
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians
-
Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians (PDF 4.7 KB)
-
Melanoma (stage III or IV) - ipilimumab: Skin Care Campaign
-
Melanoma (stage III or IV) - ipilimumab: Skin Care Campaign (PDF 97 KB)
-
Melanoma (stage III or IV) - ipilimumab: expert written personal statements
-
Melanoma (stage III or IV) - ipilimumab: Lorigan
-
Melanoma (stage III or IV) - ipilimumab: Lorigan (PDF 80 KB)
-
Melanoma (stage III or IV) - ipilimumab: Nathan
-
-
Melanoma (stage III or IV) - ipilimumab: Jackson
-
Melanoma (stage III or IV) - ipilimumab: Jackson (PDF 123 KB)
-
Melanoma (stage III or IV) - ipilimumab: details of amendments made by ERG to BMS model
-
Melanoma (stage III or IV) - ipilimumab: details of amendments made by ERG to BMS model (PDF 67 KB)
Melanoma (stage III or IV) - ipilimumab: final scope
-
Melanoma (stage III or IV) - ipilimumab: final scope
-
Melanoma (stage III or IV) - ipilimumab: final scope (PDF 53 KB)
Melanoma (stage III or IV) - ipilimumab: final matrix
-
Melanoma (stage III or IV) - ipilimumab: final matrix
-
Melanoma (stage III or IV) - ipilimumab: final matrix (PDF 64 KB)
Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the draft scope
-
Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the draft scope
-
Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the provisional matrix of consultees and commentators
-
Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the provisional matrix of consultees and commentators
-
Melanoma (stage III or IV) - ipilimumab: equality impact assessment
-
Melanoma (stage III or IV) - ipilimumab: equality impact assessment
-
Melanoma (stage III or IV) - ipilimumab: equality impact assessment (PDF 43 KB)
Melanoma (stage III or IV) - ipilimumab: draft scope
-
Melanoma (stage III or IV) - ipilimumab: draft scope
-
Melanoma (stage III or IV) - ipilimumab: draft scope (PDF 56 KB)
Melanoma (stage III or IV) - ipilimumab: provisional matrix
-
Melanoma (stage III or IV) - ipilimumab: provisional matrix
-
Melanoma (stage III or IV) - ipilimumab: provisional matrix (PDF 55 KB)